We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Organon (OGN - Free Report) was down 3.28% at $8.54. This change lagged the S&P 500's daily gain of 1.02%. On the other hand, the Dow registered a gain of 0.63%, and the technology-centric Nasdaq increased by 1.23%.
Coming into today, shares of the pharmaceutical company had gained 39.06% in the past month. In that same time, the Medical sector lost 4.81%, while the S&P 500 gained 0.63%.
Investors will be eagerly watching for the performance of Organon in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.84, marking a 17.65% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.46 billion, indicating a 3.27% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $6.16 billion, which would represent changes of -7.92% and -0.86%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Organon holds a Zacks Rank of #5 (Strong Sell).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 2.62 right now. This represents a discount compared to its industry average Forward P/E of 15.51.
It's also important to note that OGN currently trades at a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.39 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Stock Drops Despite Market Gains: Important Facts to Note
In the latest close session, Organon (OGN - Free Report) was down 3.28% at $8.54. This change lagged the S&P 500's daily gain of 1.02%. On the other hand, the Dow registered a gain of 0.63%, and the technology-centric Nasdaq increased by 1.23%.
Coming into today, shares of the pharmaceutical company had gained 39.06% in the past month. In that same time, the Medical sector lost 4.81%, while the S&P 500 gained 0.63%.
Investors will be eagerly watching for the performance of Organon in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.84, marking a 17.65% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.46 billion, indicating a 3.27% decline compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.37 per share and revenue of $6.16 billion, which would represent changes of -7.92% and -0.86%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Organon. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. As of now, Organon holds a Zacks Rank of #5 (Strong Sell).
Valuation is also important, so investors should note that Organon has a Forward P/E ratio of 2.62 right now. This represents a discount compared to its industry average Forward P/E of 15.51.
It's also important to note that OGN currently trades at a PEG ratio of 0.78. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical Services industry stood at 1.39 at the close of the market yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 144, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.